What does ESBE - PHARMA do?

ESBE - PHARMA is a pharmacy in Châtelet. Private Limited, started on 11 December 1986, 1 establishment.

What is the address of ESBE - PHARMA?

The registered office of ESBE - PHARMA is located at Grand-Rue 20, 6200 Châtelet.

Is ESBE - PHARMA still active?

Yes. According to the CBE (30 October 2026) ESBE - PHARMA is active, legal situation “Normale toestand”, started on 11 December 1986.

Is ESBE - PHARMA registered on Peppol?

Yes, ESBE - PHARMA is registered on the Peppol network with ID 0208:0430045342.

What is the enterprise number of ESBE - PHARMA?

The enterprise number of ESBE - PHARMA is BE0430045342.

When was ESBE - PHARMA founded?

ESBE - PHARMA was founded on 11 December 1986.

Who are the directors of ESBE - PHARMA?

According to the 2025 annual accounts, the directors of ESBE - PHARMA are: KARINE SPREUTELS, MICHEL BREDA.

Is ESBE - PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 December 1986; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did ESBE - PHARMA make in 2025?

ESBE - PHARMA posted a profit after taxes of € 113,949 in financial year 2025.

What is the revenue of ESBE - PHARMA?

As a small company, ESBE - PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 187,634.

Does ESBE - PHARMA have a website?

Yes, ESBE - PHARMA has a website at esbepharma.be.

ESBE - PHARMA (Private Limited) - Châtelet - BE0430045342

Dossier ESBE - PHARMA, printed on 30 October 2026 from databakkes.be/en/0430045342/esbe-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ESBE - PHARMA from Châtelet, company number BE0430045342, closed financial year 2025 with a result of € 113,949 after tax. For that financial year ESBE - PHARMA recorded a gross margin of € 187,634 and equity of € 739,799. Compared with financial year 2024, the result moved from € 101,464 to € 113,949. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Growing

€ 739,799

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 113,949

▲ 12% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 601,816

▲ 23% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 721,199.

People and assets in 2025

Vehicles and equipment

€ 5,826

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 29,001

▼ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 37,135

▲ 49% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 112,487 Gross margin 2022: € 112,487 First fiscal year in the series	€ 128,633 Gross margin 2023: € 128,633 ▲ 14% vs 2022 (€ 112,487) Favourable step	€ 169,926 Gross margin 2024: € 169,926 ▲ 32% vs 2023 (€ 128,633) Favourable step	€ 187,634 Gross margin 2025: € 187,634 ▲ 10% vs 2024 (€ 169,926) Favourable step	▲ 10%
Profit after taxes	€ 64,126 Profit after taxes 2022: € 64,126 First fiscal year in the series	€ 76,261 Profit after taxes 2023: € 76,261 ▲ 19% vs 2022 (€ 64,126) Favourable step	€ 101,464 Profit after taxes 2024: € 101,464 ▲ 33% vs 2023 (€ 76,261) Favourable step	€ 113,949 Profit after taxes 2025: € 113,949 ▲ 12% vs 2024 (€ 101,464) Favourable step	▲ 12%
Equity	€ 448,009 Equity 2022: € 448,009 First fiscal year in the series	€ 524,271 Equity 2023: € 524,271 ▲ 17% vs 2022 (€ 448,009) Favourable step	€ 625,734 Equity 2024: € 625,734 ▲ 19% vs 2023 (€ 524,271) Favourable step	€ 739,799 Equity 2025: € 739,799 ▲ 18% vs 2024 (€ 625,734) Favourable step	▲ 18%
Total debts	€ 86,214 Total debts 2022: € 86,214 First fiscal year in the series	€ 79,887 Total debts 2023: € 79,887 ▼ 7% vs 2022 (€ 86,214) Favourable step	€ 72,470 Total debts 2024: € 72,470 ▼ 9% vs 2023 (€ 79,887) Favourable step	€ 68,363 Total debts 2025: € 68,363 ▼ 6% vs 2024 (€ 72,470) Favourable step	▼ 6%
Cash	€ 348,177 Cash 2022: € 348,177 First fiscal year in the series	€ 375,068 Cash 2023: € 375,068 ▲ 8% vs 2022 (€ 348,177) Favourable step	€ 489,103 Cash 2024: € 489,103 ▲ 30% vs 2023 (€ 375,068) Favourable step	€ 601,816 Cash 2025: € 601,816 ▲ 23% vs 2024 (€ 489,103) Favourable step	▲ 23%
Retained profit	€ 429,409 Retained profit 2022: € 429,409 First fiscal year in the series	€ 505,671 Retained profit 2023: € 505,671 ▲ 18% vs 2022 (€ 429,409) Favourable step	€ 607,134 Retained profit 2024: € 607,134 ▲ 20% vs 2023 (€ 505,671) Favourable step	€ 721,199 Retained profit 2025: € 721,199 ▲ 19% vs 2024 (€ 607,134) Favourable step	▲ 19%
Balance sheet total	€ 534,223 Balance sheet total 2022: € 534,223 First fiscal year in the series	€ 604,158 Balance sheet total 2023: € 604,158 ▲ 13% vs 2022 (€ 534,223) Unchanged	€ 698,204 Balance sheet total 2024: € 698,204 ▲ 16% vs 2023 (€ 604,158) Unchanged	€ 808,162 Balance sheet total 2025: € 808,162 ▲ 16% vs 2024 (€ 698,204) Unchanged	▲ 16%

Key figures of ESBE - PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ESBE - PHARMA?

What happened at ESBE - PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 31, 2026 New annual accounts for financial year 2025: profit of € 113,949 (▲ 12% vs 2024). Source: NBB ↗
Feb 13, 1987 New establishment in Châtelet. KBO
Dec 11, 1986 Start of the company according to the CBE. KBO

In short

From € 64,126 profit in 2022 to € 113,949 profit in 2025.

Paid € 172,728 in corporate taxes since 2022.

Best year ever: 2025, with € 113,949 profit.

Original PDFs at the National Bank ↗

Management

KARINE SPREUTELS MICHEL BREDA

ESBE - PHARMA

Behind ESBE - PHARMA are KARINE SPREUTELS and MICHEL BREDA.

Directors

According to the 2025 annual accounts

KARINE SPREUTELS

Director

MICHEL BREDA

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Grand-Rue 20

6200 Châtelet

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS esbepharma.be

About

Technologies

Advanced Custom FieldsApacheElementorFont AwesomeGoogle FontsGoogle MapsPHPPWASwiperWordPressYoast SEOjQueryjQuery UIlazysizesreCAPTCHA

Hosting & Email

Email provider

Self-hosted

Hosting

HETZNER-AS, DE

Website info

HTTPS Ja

Languages FR

Features

Webshop Blog Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number

0430.045.342

VAT number

BE 0430.045.342

Registered office

Grand-Rue 20, 6200 Châtelet

Names & denominations

ESBE - PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

11 December 1986

Peppol

Active · Active since 13 Dec 2025

Contact

esbepharma.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

ESBE - PHARMA

Financials

What happened to ESBE - PHARMA?

Management

Directors

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions